Severe Psoriasis: 2018 Pipeline Insights Featuring Eli Lilly, AstraZeneca, Celgene, Boehringer Ingelheim and Others - ResearchAndMarkets.com

DUBLIN--()--The "Severe Psoriasis - Pipeline Insight, 2018" drug pipelines report has been added to ResearchAndMarkets.com's offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Severe Psoriasis development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Severe Psoriasis pipeline products by developmental stage, product type, molecule type, and administration route.

Scope

  • The report provides a snapshot of the pipeline development for the Severe Psoriasis
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Severe Psoriasis
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Severe Psoriasis
  • The report also covers the dormant and discontinued pipeline projects related to the Severe Psoriasis

Companies Featured

  • Almirall
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Eli Lilly and Company
  • Forward Pharma A/S
  • Galectin Therapeutics
  • Idera Pharmaceuticals

Key Topics Covered

1. Report Introduction

2. Severe Psoriasis Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/spph3t/severe_psoriasis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Psoriasis Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Psoriasis Drugs